MAPPYACTS study: a first step towards the hyper-personalized oncology of the future! The final results of this international study, co-financed by Imagine for Margo, lay the foundations for access to precision medicine for the cancer youngest patients when conventional treatment has failed. This clinical research program, the results of which have been published in the journal Cancer Discovery and will be presented on April 12 at the American Association for Cancer Research (AACR) congress, sequences the genome of tumors to better understand their evolution in order to adapt treatments.

MAPPYACTS made it possible to find in 69% of patients, one or more abnormalities likely to be specifically targeted by a new drug. 30% of these patients were able to benefit from a new targeted therapy and more than half (57%) of these innovative treatments were administered as part of the European AcSé-ESMART therapeutic trial, which we are also co-funding. A hope for all the little warriors who fight against the disease.

Today, this sequencing is funded by the State as part of the France Genomics Medicine program. This device allows all children and teenagers with cancer to benefit from a complete molecular analysis. Sequencing results also fed a molecular database and 50 projects

Research is currently underway to better understand childhood and teenagers cancers using MAPPYACTS data.

We were able to co-finance this study up to 1,734,000 euros thanks to the 2017 and 2019 editions of our Children without Cancer race and the 2019 edition of the Rally du Coeur – Paris.

Help us continue to accelerate research by participating in the next editions of our solidarity races on May 19 in La Défense and on September 25 in Saint-Cloud or online.

Learn more about the results of the MAPPYACTS study.